Navigation Links
Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
Date:9/10/2009

DALLAS, Sept. 10 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), provided an update today on the Company's clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies. Access' clinical development team recently met with its partners Aosaikang Medicinal Group (ASK) in Nanjing, China and JCOM, Ltd. ("JCOM") in Seoul, Korea, together with key opinion leaders in oncology indications to discuss the protocols for the three planned ProLindac combination studies. Access and its partners are finalizing development plans and protocols for clinical trials strategically designed to examine ProLindac in combination with gemcitabine and/or taxol in hepatocellular carcinoma (a form of liver cancer), pancreatic cancer and recurrent ovarian cancer.

Access previously announced positive safety and efficacy results from its Phase 2 monotherapy clinical study of ProLindac(TM) in late-stage, heavily pretreated ovarian cancer patients. In this study, 66% of patients who received the highest dose achieved clinically meaningful disease stabilization according to

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference
2. NuAire Laboratory Economic Stimulus Package -- Free Accessories or Factory Options
3. One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions
4. Understanding Managed Markets: Effective Market Research Structures & Activities to Maximize Payer Access & Insights
5. Access Pharmaceuticals CEO Interviewed on Financial Website
6. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
7. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
8. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
9. Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China
10. Cyprotex Launches Cloe(R) Gateway, its Secure web Portal for Access to Cyprotex Services Including an Enhanced Version of Cloe(R) PK.
11. Ochsner and LSUHSC Partner to Provide Better Local Access to Comprehensive Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cbgl72/middle_east_and ) has ... Africa Biomedical Sensors Market - Growth, Trends & Forecasts ... The Middle East & Africa ... 2018 at a CAGR of 3.26% over the period ... sensors that are adaptable to the genetic formulation of ...
(Date:8/31/2015)... , Aug. 31, 2015  RXi Pharmaceuticals Corporation ... on discovering and developing innovative therapies primarily in ... that the 30-day review period following the filing ... ocular indications with the U.S. Food and Drug ... now active. Logo -  ...
(Date:8/31/2015)... SAN FRANCISCO, Calif. , Aug. 31, 2015 /PRNewswire/ ... the discovery and development of novel cancer immunotherapies, announced ... M.D., Ph.D., as Chief Executive Officer and William ... Wong and Ho join an experienced management team led ... Jordan Fridman , Ph.D., Chief Scientific Officer; ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... high priority in the drug development approval process. Thus, innovator companies must understand ... Regis Technologies, Inc., a Chicago-based CMO, has been hosting multiple educational panels and ...
Breaking Biology Technology:Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
... The state will give $250,000 in tax credits to C3 ... an 18,000-square-foot facility in Appleton's Northeast Business Park. , ,According ... create 28 jobs in the area. The credits are part ... aside $5 million in tax credits for each of eight ...
... up with UW-Eau Claire, UW-Stout and several other tech ... in the state. , ,Nanotechnology deals with particles one ... physical properties of matter begin to give way to ... understand. The potential of arranging nanoparticles, which scientists long ...
... the University of Wisconsin-Madison are taking another look at some ... That's what scientists call the way sounds change as you ... example, a jackhammer or a siren will sound higher pitched ... ,But there's an inverse Doppler effect, too, predicted ...
Cached Biology Technology:Chippewa Valley Technical College helps pioneer nanotech program, incubator 2Chippewa Valley Technical College helps pioneer nanotech program, incubator 3Chippewa Valley Technical College helps pioneer nanotech program, incubator 4
(Date:8/17/2015)... , Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... new sales campaign for Q4 2015. The new marketing ... team consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) ... Group is a leader in retail driven marketing and ...
(Date:8/12/2015)... 12, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that four of its fingerprint ID ... officially been named FIDO Certified™ by the Fast ... certification, Synaptics, Natural ID™ fingerprint solutions are fully ... (UAF) standard and are interoperable among other products ...
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Rep. Honda to Visit Crossmatch in Redwood City 2
... when the Food and Drug Administration is reconsidering the ... study offers further evidence to support a University of ... treatment may be in order. Richard ... Houston College of Pharmacy (UHCOP), has been investigating whether ...
... Ill. -- Most people know that too much sodium from ... that people trying to lower their blood pressure should also ... to sodium. Researchers found that the ratio of sodium-to-potassium ... disease than sodium or potassium alone. "There isn,t ...
... the first clinical evidence that gene therapy reduces symptoms ... this promising treatment which has endured a sometimes turbulent ... Human Gene Therapy the findings stem from ... conducted in Germany and led by an investigator at ...
Cached Biology News:New asthma research opposes current drug treatment, says UH prof 2New asthma research opposes current drug treatment, says UH prof 3New asthma research opposes current drug treatment, says UH prof 4Cutting salt isn't the only way to reduce blood pressure 2Gene therapy demonstrates benefit in patients with rheumatoid arthritis 2Gene therapy demonstrates benefit in patients with rheumatoid arthritis 3
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Human OSCAR MAb (Clone 259501)...
Human/Mouse G9a/EHMT2 MAb (Clone A8620A) Keywords: Eu-HMTase2...
Human M-CSF...
Biology Products: